Drugs that contain Lapatinib Ditosylate
1. Tykerb patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6391874 | NOVARTIS | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul, 2017
(6 years ago) | |
| US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
| US6713485 | NOVARTIS | Heterocyclic compounds |
Sep, 2020
(3 years ago) | |
| US7157466 | NOVARTIS | Quinazoline ditosylate salt compounds |
Nov, 2021
(2 years ago) | |
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6828320 | NOVARTIS | Heterocyclic compounds |
Jul, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-235) | Dec 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Treatment: Treatment of patients with breast cancer whose tumors overexpress the her2 receptor; Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received...
Dosage: TABLET;ORAL
How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage
TYKERB family patents
